Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

99 (399) -

-------------------------------------------------------------------------

Net (loss) income

for the period (59,357) 63,052 3,695 4,585 55,905 60,490

-------------------------------------------------------------------------

Basic net (loss)

income per common

share from

continuing

operations (0.56) 0.04 0.14 0.71

Diluted net (loss)

income per common

share from

continuing

operations (0.56) 0.04 0.14 0.71

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average

shares outstanding

(000's) - basic 85,015 85,015 84,752 84,752

Weighted average

shares outstanding

(000's) - diluted 85,015 85,390 85,437 85,437

-------------------------------------------------------------------------

-------------------------------------------------------------------------

a. One time revenue gain resulting from the up-front monetization of a

royalty revenue stream to be received from our collaboration and

distribution partnership with Orthovita.

b. Amounts accrued for costs incurred, and potential future costs,

related to our offer to accept returns of Contour Threads brand

product as part of consolidation and discontinuation of the Contour

Threads brand name, coincident with the launch of our Quill SRS brand

name.

c. Non-recurring, non-operating revenue as derived from license

agreements with Histogenics Corporation ($0.4 million in 2007),

Symphony Medical ($0.2 million in 2007) and other license revenue,

net of license fees due to licensors. In 2006, as der
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 2Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 3Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 5Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 6Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 7Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 8SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3Eidogen-Sertanty Licenses TIP to the FDA 2